Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting
-- Oral Selinexor Achieves 26.2% Overall Response Rate in STORM Study, 4.4 Month Median Duration of Response, 8.6 Month Median Overall Survival and 15.6 Month Median Survival in Patients with MR or Better -- -- Once Weekly Oral Selinexor in Combination with Darzalex ® and Low Dose Dexamethasone
View HTML
Toggle Summary Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting
-- 29.6% Overall Response Rate Including 9.6% Complete Response Rate -- -- Amongst the Patients with Complete or Partial Response, Median Duration of Response was 9.2 Months and Median Overall Survival was 29.7 months -- -- Company Plans to Submit New Drug Application to the FDA in the First Half
View HTML
Toggle Summary Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
-- U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review; Assigns PDUFA Action Date of April 6, 2019 -- -- Fast Track Designation Received for Selinexor in Relapsed or Refractory DLBCL; Top-Line Phase 2b SADAL Data in DLBCL Selected for
View HTML
Toggle Summary Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
NEWTON, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound
View HTML
Toggle Summary Karyopharm to Present at the Jefferies 2018 London Healthcare Conference
NEWTON, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14,
View HTML
Toggle Summary Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th
Ceremony to Commemorate Five-Year Listing Anniversary NEWTON, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and Chief
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 127,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting
--  Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented --  --  Additional Results from the Pivotal Phase 2b STORM Study in Penta-Refractory Multiple Myeloma and Updated Phase 1b/2 STOMP Data in Relapsed or Refractory Multiple Myeloma to be Highlighted in Oral Presentations -- 
View HTML
Toggle Summary Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018
-- Conference Call Scheduled for Thursday, November 8, 2018 at 8:30 a.m. ET --  NEWTON, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2018 financial results on
View HTML
Toggle Summary Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers’ Option
NEWTON, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes”) pursuant to
View HTML